Clinical Trial Update: Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating an epitope peptide for advanced non-small cell lung cancer has completed safety and efficacy assessments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Epitope Peptide

Snippet

Sponsor: Shiga University | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED